View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
January 26, 2010

CSL Behring Launches Berinert Expert Network

CSL Behring has launched the Berinert Expert Network (B.E.N.), a full-service support program for healthcare providers and for hereditary angioedema (HAE) patients and their caregivers. In October, the FDA granted marketing approval for Berinert C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of HAE in adult and adolescent patients.

By CBR Staff Writer

The safety and efficacy of Berinert for prophylactic therapy has not been established. Berinert is now available through specialty pharmacies and distributors in the US.

Robert Lefebvre, vice president and general manager of US commercial operations at CSL Behring, said: “The Berinert Expert Network is an excellent example of CSL Behring’s commitment to going ‘above and beyond’ for patients and healthcare professionals by offering innovative products and high-quality support programs designed to meet their needs.

“B.E.N. will ensure that individuals in the HAE community, including healthcare providers, patients and their caregivers, have access to Berinert and will have a single point-of-contact to assist with helping them to manage their medical condition.”

In clinical trials, the median time to onset of relief with Berinert was 48 minutes as compared to more than four hours with placebo. As claimed, B.E.N helps patients connect with medical experts who can provide information about their condition, and details on Berinert.

Content from our partners
How designers are leveraging tech to apply the brakes to fast fashion
Why the tech sector must embrace faster, smarter talent recruitment
Sherif Tawfik: The Middle East and Africa are ready to lead on the climate

In addition, through B.E.N., HAE patients will be able to connect with other patients via the US Hereditary Angioedema Association (HAEA). In this way, patients can benefit from additional valuable programs and resources designed for and by people with HAE.

The approval of Berinert was based on the results of the phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (IMPACT), which studied the efficacy and safety of C1-inhibitor (C1-INH) concentrate. The safety and efficacy of Berinert for prophylactic therapy have not been established.

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.